• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

3

CATEGORIES

  • 8
  • 3
  • 2
  • 1

PRICE

9
10
13
13

PUBLISHED

1
2
4
13

PRODUCT TYPE

9
4

Search "Micromet, Inc. - SWOT Analysis" returned 13 results.

PRODUCT TITLE
Micromet, Inc. (MITI) - Financial and Strategic SWOT Analysis Review Micromet, Inc. (MITI) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Micromet, Inc. (MITI) - Financial and Strategic SWOT Analysis Review

Micromet, Inc. (MITI) - Financial and Strategic SWOT Analysis Review Summary Micromet, Inc. (Micromet) is a biopharmaceutical company engaged in the development of novel antibody-based therapeutic...

September 2011
FROM
Micromet, Inc.: Company Profile and SWOT Analysis Micromet, Inc.: Company Profile and SWOT Analysis - Product Thumbnail Image

Micromet, Inc.: Company Profile and SWOT Analysis

Synopsis ICD Research's "Micromet, Inc.: Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, business...

December 2011
FROM
Micromet, Inc.: SWOT Analysis & Company Profile Micromet, Inc.: SWOT Analysis & Company Profile - Product Thumbnail Image

Micromet, Inc.: SWOT Analysis & Company Profile

Synopsis Business Review’s Micromet, Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company. Summary This SWOT Analysis company...

February 2010
FROM

Micromet, Inc. - SWOT, Strategy and Corporate Finance Report

Micromet, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product...

January 2013
FROM
Micromet Inc: Premium Company Profile Micromet Inc: Premium Company Profile - Product Thumbnail Image

Micromet Inc: Premium Company Profile

Micromet’s main focus is to develop and commercialize products for the treatment of cancer and inflammatory and autoimmune diseases. The company continues to leverage the capability for their early-stage...

April 2008
FROM
Bayer Schering Pharma AG (SHRGY) - Strategic Analysis Review Bayer Schering Pharma AG (SHRGY) - Strategic Analysis Review - Product Thumbnail Image

Bayer Schering Pharma AG (SHRGY) - Strategic Analysis Review

Bayer Schering Pharma AG (Bayer Schering) is a global pharmaceutical company, engaged in the development, manufacturing and selling of pharmaceutical products. It is also involved in the research for...

September 2010
FROM

Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT Analysis Review

Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

May 2014
FROM
Tamir Biotechnology, Inc. (ACEL) - Financial and Strategic SWOT Analysis Review Tamir Biotechnology, Inc. (ACEL) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Tamir Biotechnology, Inc. (ACEL) - Financial and Strategic SWOT Analysis Review

Tamir Biotechnology, Inc. (ACEL) - Financial and Strategic SWOT Analysis Review Summary Tamir Biotechnology, Inc. (formerly known as Alfacell Corporation) is a biopharmaceutical company engaged in...

September 2011
FROM

Antibody Drug Conjugates Market, 2012-2023

Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology This class of...

May 2013
FROM

Dendreon Corporation (DNDN) - Financial and Strategic SWOT Analysis Review

Dendreon Corporation (DNDN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

April 2014
FROM

Bispecific Antibody Therapeutics Market, 2013 - 2023

Antibody based therapeutics are the fastest growing segment of the drugs and biologics market There are 30 approved antibody based therapeutics available in the US and European markets since the launch...

September 2013
FROM
Seattle Genetics, Inc. (SGEN) - Financial and Strategic Analysis Review Seattle Genetics, Inc. (SGEN) - Financial and Strategic Analysis Review - Product Thumbnail Image

Seattle Genetics, Inc. (SGEN) - Financial and Strategic Analysis Review

Seattle Genetics, Inc. (Seattle) is a biotechnology company engaged in the discovery and the development of monoclonal antibody-based drugs to treat cancer and autoimmune diseases. The company's lead...

August 2010
FROM

Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024

Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies Generally addressed as the marriage of an antibody...

August 2014
FROM
Loading Indicator